Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Heidelberglaan 100, room G02.523, 3584 CX, Utrecht, The Netherlands.
J Mol Med (Berl). 2013 Aug;91(8):1001-12. doi: 10.1007/s00109-013-1017-1. Epub 2013 Apr 27.
Instigated by the discovery of adult cardiac progenitor cells, cell replacement therapy has become a promising option for myocardial repair in the past decade. We have previously shown that human-derived cardiomyocyte progenitor cells (hCMPCs) can differentiate into cardiomyocyte-, endothelial-, and smooth muscle-like cells in vitro, and in vivo after transplantation in a mouse model of myocardial infarction, resulting in preservation of cardiac function. However, to allow successful repopulation of the injured myocardium, it is of key importance to restore myocardial perfusion by the formation of new vasculature. Several studies have shown that microRNAs regulate vascular differentiation of different stem/progenitor cells. Here, we show that miR-1 is upregulated in hCMPCs during angiogenic differentiation. Upregulation of miR-1 enhanced the formation of vascular tubes on Matrigel and within a collagen matrix, and also increased hCMPC motility, as shown by planar and transwell migration assays. By western blot, qRT-PCR and luciferase reporter assays, miR-1 was found to directly target and inhibit the expression of sprouty-related EVH1 domain-containing protein 1 (Spred1). Knocking down Spred1 phenocopies the functional effect seen for miR-1 upregulation. Using a systems biology approach, we found that in hCMPCs, miR-1 is proposed to control a network of genes predominantly involved in angiogenesis-related processes, including the Spred1 pathway. Our data shows that by upregulation of miR-1, the angiogenic differentiation of hCMPCs can be enhanced, which may be used as a new therapeutic approach to improve the efficiency of cell-based therapy for cardiac regeneration by enhancing the formation of new vasculature.
受成人心肌祖细胞发现的启发,细胞替代疗法在过去十年中已成为心肌修复的一种有前途的选择。我们之前已经表明,人源心肌祖细胞(hCMPCs)可以在体外分化为心肌细胞、内皮细胞和平滑肌样细胞,并且在心肌梗死的小鼠模型中移植后体内分化为这些细胞,从而保持心脏功能。然而,为了成功地使受损的心肌重新充满细胞,通过形成新的血管来恢复心肌灌注至关重要。几项研究表明,microRNAs 调节不同干细胞/祖细胞的血管分化。在这里,我们显示 miR-1 在 hCMPCs 血管生成分化过程中上调。miR-1 的上调增强了 Matrigel 和胶原基质中血管管腔的形成,并通过平面和 Transwell 迁移测定显示出增加了 hCMPC 的迁移能力。通过 Western blot、qRT-PCR 和荧光素酶报告基因测定,发现 miR-1 直接靶向并抑制芽生相关 EVH1 结构域包含蛋白 1(Spred1)的表达。下调 Spred1 可模拟 miR-1 上调所观察到的功能效应。使用系统生物学方法,我们发现 miR-1 在 hCMPCs 中,控制一个主要涉及血管生成相关过程的基因网络,包括 Spred1 通路。我们的数据表明,通过上调 miR-1,可以增强 hCMPCs 的血管生成分化,这可以作为一种新的治疗方法,通过增强新血管的形成来提高基于细胞的心脏再生治疗的效率。